Contura’s soft tissue fillers target both the medical and aesthetic markets, with the two main products being Bulkamid and Aquamid.
Bulkamid is a urethral bulking agent used in the treatment of female urinary stress incontinence. The procedure is performed under endoscopic control using the Bulkamid Urethral Bulking System (patents pending). Clinical studies have been successfully performed in Europe and more recently in the United states.
Aquamid is a soft volume filler used to rejuvenate the face and enhance facial features. To date, plastic surgeons, dermatologists and cosmetic physicians have treated more than a quarter of a million people with Aquamid.
Aquamid is available through a network of distributors covering 40 countries. Aquamid has been evaluated in several successful clinical trials, including a major clinical trial in the United States.
Contura is a medical technology company based in Denmark that develops and commercialises soft tissue fillers.
Contura was established in 2000 and acquired by SEP in May 2013.
Contura’s development, manufacturing and testing processes are in compliance with the European Medical Devices directive 93/42/EEC and meet the standards required to obtain ISO13485:2012, ISO 9001:2008 certification, CMDCAS SOR/98-282.